eligibility_summary
Adults (≥18) with MM (IMWG), ≥3 prior lines incl PI, IMiD, anti‑CD38 or double‑refractory, progression ≤12 mo, measurable disease, ECOG 0–1, adequate organ function, contraception. Prior BCMA allowed if ≥PR and BCMA+. Exclude: GVHD, Allo‑HSCT or Auto‑HSCT ≤12 wks, recent therapy or high‑dose steroids, serious cardiac/systemic illness, organ transplant, CNS disease, PCL/WM/POEMS/AL, recent surgery, active infection or viral+, pregnancy, recent neuro events, unresolved tox, other compromising conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CT103A, a fully human BCMA-targeted CAR-T cell therapy (genetically modified autologous T cells). Mechanism: T cells are engineered with a fully human anti-BCMA scFv, BCMA engagement triggers CD3ζ signaling to activate T cells, induce cytokine release, and mediate cytotoxic killing. A 4-1BB (CD137) co-stimulatory domain enhances proliferation, persistence, and antitumor activity. Targets: BCMA-expressing cells—primarily malignant plasma cells in multiple myeloma—and may also affect normal BCMA+ plasma cells. Key pathways/cells: CAR signaling via CD3ζ and 4-1BB, T-cell effector functions (granzyme/perforin, cytokines). Study: Phase Ib, single-arm, open-label in adults with relapsed/refractory multiple myeloma after ≥3 prior therapies, lymphodepletion precedes a single CT103A infusion, evaluates safety, efficacy, PK/PD, and immunogenicity.